DETECT V/CHEVENDO - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

被引：2
|
作者：
Krause, S.
Friedl, T.
Fehm, T.
Romashova, T.
Fasching, P. A.
Schneeweiss, A.
Mueller, V.
Taran, F-A
Polasik, A.
Tzschaschel, M.
De Gregorio, A.
Meier-Stiegen, F.
Janni, W.
Huober, J.
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[3] Univ Hosp Erlangen, Erlangen, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[7] Univ Hosp Tubingen, Tubingen, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
    Lin, Mingxi
    Chen, Yang
    Jin, Yizi
    Hu, Xichun
    Zhang, Jian
    JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
  • [32] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
    Hua, Xin
    Bi, Xi-Wen
    Zhao, Jian-Li
    Shi, Yan-Xia
    Lin, Ying
    Wu, Zhi-Yong
    Zhang, Yuan-Qi
    Zhang, Le-Hong
    Zhang, An-Qing
    Huang, Heng
    Liu, Xin-Mei
    Xu, Fei
    Guo, Ying
    Xia, Wen
    Hong, Ruo-Xi
    Jiang, Kui-Kui
    Xue, Cong
    An, Xin
    Zhong, Yong-Yi
    Wang, Shu-Sen
    Huang, Jia-Jia
    Yuan, Zhong-Yu
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 637 - 645
  • [33] Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer
    Takada, Koji
    Kashiwagi, Shinichiro
    Goto, Wataru
    Asano, Yuka
    Morisaki, Tamami
    Fujita, Hisakazu
    Takashima, Tsutomu
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2018, 38 (04) : 2285 - 2294
  • [34] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [35] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [36] First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
    Blumenthal, Gideon M.
    Scher, Nancy S.
    Cortazar, Patricia
    Chattopadhyay, Somesh
    Tang, Shenghui
    Song, Pengfei
    Liu, Qi
    Ringgold, Kimberly
    Pilaro, Anne M.
    Tilley, Amy
    King, Kathryn E.
    Graham, Laurie
    Rellahan, Barbara L.
    Weinberg, Wendy C.
    Chi, Bo
    Thomas, Colleen
    Hughes, Patricia
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2013, 19 (18) : 4911 - 4916
  • [37] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] STUDY OF S-1/TRASTUZUMAB COMBINATION THERAPY FOR HER2-POSITIVE METASTATIC BREAST CANCER
    不详
    ANNALS OF ONCOLOGY, 2010, 21 : 64 - 64
  • [39] Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer
    Davis, Andrew A.
    Luo, Jingqin
    Zheng, Tiantian
    Dai, Chao
    Dong, Xiaoxi
    Tan, Lu
    Suresh, Rama
    Ademuyiwa, Foluso O.
    Rigden, Caron
    Rearden, Timothy P.
    Clifton, Katherine
    Weilbaecher, Katherine
    Frith, Ashley
    Tandra, Pavan K.
    Summa, Tracy
    Haas, Brittney
    Thomas, Shana
    Hernandez-Aya, Leonel F.
    Peterson, Lindsay L.
    Wang, Xiaohong
    Luo, Shujun J.
    Zhou, Kemin
    Du, Pan
    Jia, Shidong
    King, Bonnie L.
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1719 - 1729
  • [40] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
    Printz, Carrie
    CANCER, 2020, 126 (09) : 1827 - 1827
12345